Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma
November 18, 2009
- Initiation of a Phase II trial in multiple myeloma evaluating the combination of IPH 2101 - a fully human anti-KIR monoclonal antibody stimulating NK cells' anti-tumoral activity, with Celgene’s REVLIMID®
- Growing body of evidence in hematological malignancies supports REVLIMID® enhanced NK-mediated cytotoxicity and its potential synergy with IPH 2101’s mechanism of action
| Download Area |
|---|
| PR in english |
| CP en français |